Tivic Health shares surge 22.29% after-hours after securing BARDA meeting for Entolimod's acute radiation syndrome development.

Tivic Health Systems (TIVC) surged 22.29% in after-hours trading following the announcement of securing a pivotal meeting with the Biomedical Advanced Research and Development Authority (BARDA) for its drug Entolimod. The meeting, focused on discussing development pathways for treating acute radiation syndrome, aligns with Entolimod’s existing FDA Fast Track and Orphan Drug designations. The event underscores potential government partnerships or acquisition opportunities, as well as progress toward a biologics license application. The stock’s sharp rise reflects optimism around BARDA’s involvement in advancing Entolimod’s commercial and regulatory trajectory, particularly for emergency medical countermeasures.